Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma (Englisch)
- Neue Suche nach: Takada, Hitomi
- Neue Suche nach: Yamashita, Koji
- Neue Suche nach: Osawa, Leona
- Neue Suche nach: Komiyama, Yasuyuki
- Neue Suche nach: Muraoka, Masaru
- Neue Suche nach: Suzuki, Yuichiro
- Neue Suche nach: Sato, Mitsuaki
- Neue Suche nach: Kobayashi, Shoji
- Neue Suche nach: Yoshida, Takashi
- Neue Suche nach: Takano, Shinichi
- Neue Suche nach: Maekawa, Shinya
- Neue Suche nach: Enomoto, Nobuyuki
- Neue Suche nach: Takada, Hitomi
- Neue Suche nach: Yamashita, Koji
- Neue Suche nach: Osawa, Leona
- Neue Suche nach: Komiyama, Yasuyuki
- Neue Suche nach: Muraoka, Masaru
- Neue Suche nach: Suzuki, Yuichiro
- Neue Suche nach: Sato, Mitsuaki
- Neue Suche nach: Kobayashi, Shoji
- Neue Suche nach: Yoshida, Takashi
- Neue Suche nach: Takano, Shinichi
- Neue Suche nach: Maekawa, Shinya
- Neue Suche nach: Enomoto, Nobuyuki
In:
Hepatology Research
;
54
, 2
;
162-173
;
2024
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma
-
Beteiligte:Takada, Hitomi ( Autor:in ) / Yamashita, Koji ( Autor:in ) / Osawa, Leona ( Autor:in ) / Komiyama, Yasuyuki ( Autor:in ) / Muraoka, Masaru ( Autor:in ) / Suzuki, Yuichiro ( Autor:in ) / Sato, Mitsuaki ( Autor:in ) / Kobayashi, Shoji ( Autor:in ) / Yoshida, Takashi ( Autor:in ) / Takano, Shinichi ( Autor:in )
-
Erschienen in:Hepatology Research ; 54, 2 ; 162-173
-
Verlag:
-
Erscheinungsdatum:01.02.2024
-
Format / Umfang:12 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 54, Ausgabe 2
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 117
-
Issue Information| 2024
- 120
-
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapyArai, Jun / Ito, Kiyoaki et al. | 2024
- 122
-
Cost‐effectiveness of hepatitis E virus vaccination strategyKato, Hideaki et al. | 2024
- 125
-
New concept in fatty liver diseasesTokushige, Katsutoshi et al. | 2024
- 131
-
Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patientsInoue, Jun / Akahane, Takehiro / Kobayashi, Tomoo / Kimura, Osamu / Sato, Kosuke / Ninomiya, Masashi / Iwata, Tomoaki / Takai, Satoshi / Kisara, Norihiro / Sato, Toshihiro et al. | 2024
- 142
-
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in ChinaCui, Tingting / Zhang, Xuefeng / Wang, Qiang / Yue, Na / Bao, Changjun / Jiang, Renjie / Xu, Shilin / Yuan, Zhaohu / Qian, Yunke / Chen, Liling et al. | 2024
- 151
-
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failureTu, Yasi / Ji, Feiyang / Yang, Jing / Rao, Qunfang / Wu, Haiquan / Xie, Zhongyang / Zhang, Sainan / Hou, Zhouhua / Wu, Daxian et al. | 2024
- 162
-
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinomaTakada, Hitomi / Yamashita, Koji / Osawa, Leona / Komiyama, Yasuyuki / Muraoka, Masaru / Suzuki, Yuichiro / Sato, Mitsuaki / Kobayashi, Shoji / Yoshida, Takashi / Takano, Shinichi et al. | 2024
- 174
-
Rho GTPase‐activating protein 1 promotes hepatocellular carcinoma progression via modulation by CircPIP5K1A/MiR‐101‐3pXu, Yanni / Liu, Xiaodi / Cao, Jincheng / Wu, Ye / Jiang, Qiongchao / Luo, Baoming et al. | 2024
- 189
-
Protein profiles reveal MSH6/MSH2 as a potential biomarker for hepatocellular carcinoma with microvascular invasionHong, Shengqian / Zhang, Jialing / Liu, Shiqi / Jin, Quan / Li, Jingqi / Xia, Anliang / Xu, JianBo et al. | 2024
- 201
-
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter studyFukunaga, Shuhei / Mukasa, Michita / Nakane, Tomoyuki / Nakano, Dan / Tsutsumi, Tsubasa / Chou, Tomonori / Tanaka, Hiroshi / Hayashi, Daiki / Minami, Shinpei / Ohuchi, Akihiro et al. | 2024
- 213
-
Integrative prediction of metabolic dysfunction‐associated fatty liver disease by endogenous fructose and related metabolismChung, Hsien‐Hui et al. | 2024